0.7547

17.05% 0.1148

Athira Pharma Inc (ATHA)

Overview News Price History Option Chain Financials Discussions Forecast

Athira Pharma Inc stock is traded at $0.7547, with a volume of 10.94M. It is up +17.05% in the last 24 hours and up +76.24% over the past month. Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Previous Close:

$0.6399

Open:

$0.6394

24h Volume:

10.94M

Relative Volume:

2.30

Market Cap:

$24.60M

Revenue:

Net Income/Loss:

$-117.67M

P/E Ratio:

-0.2667

EPS:

-2.83

Net Cash Flow:

$-101.06M

1W Performance:

+54.72%

1M Performance:

+76.24%

6M Performance:

-61.79%

1Y Performance:

-53.77%

1-Day Range:

$0.6013

$0.81

1-Week Range:

$0.42

$0.81

52-Week Range:

$0.4115

$4.2984

Athira Pharma Inc Stock (ATHA) Company Profile

Name

Athira Pharma Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(425) 620-8501

Address

18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ATHA's Discussions on Twitter

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Jul-07-22	Initiated	Mizuho	Buy
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold
Jun-23-22	Downgrade	Stifel	Buy → Hold
May-10-22	Initiated	BTIG Research	Buy
Apr-21-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Goldman	Neutral
Oct-13-20	Initiated	Goldman	Buy
Oct-13-20	Initiated	JMP Securities	Mkt Outperform
Oct-13-20	Initiated	Jefferies	Buy
Oct-13-20	Initiated	Stifel	Buy

View All

Athira Pharma Inc Stock (ATHA) Latest News

08:05 AM

What You Didn’t Know About Athira Pharma Inc (NASDAQ: ATHA) This Week - Stocks Register

08:05 AM

Nov 04, 2024

Errors Lower Fee Award For Athira Pharma Investors' Counsel - Law360

Nov 04, 2024

US Penny Stocks: November 2024's Top Picks To Consider - Simply Wall St

Nov 04, 2024

Oct 31, 2024

Perceptive Advisors LLC Acquires Significant Stake in Athira Pha - GuruFocus.com

Oct 31, 2024

Oct 26, 2024

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - MSN

Oct 26, 2024

Oct 22, 2024

Athira Pharma to Present Results from Phase 2/3 LIFT-AD - GlobeNewswire

Oct 22, 2024

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting - StockTitan

Oct 22, 2024

Oct 18, 2024

Athira Pharma faces Nasdaq delisting over share price - Investing.com

Oct 18, 2024

Oct 16, 2024

A closer look at Athira Pharma Inc (ATHA)’s stock price trends - US Post News

Oct 16, 2024

Oct 07, 2024

A year in review: Athira Pharma Inc (ATHA)’s performance in the last year - US Post News

Oct 07, 2024

A Guide To The Risks Of Investing In Athira Pharma Inc (ATHA) - Knox Daily

Oct 07, 2024

Analytical Overview: Athira Pharma Inc (ATHA)’s Ratios Tell a Financial Story - The Dwinnex

Oct 07, 2024

Sep 29, 2024

Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World

Sep 29, 2024

Sep 27, 2024

Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com

Sep 27, 2024